1. Scaling Up Access and Rational Drug Use Anthony D. So, MD, MPA Program on Global Health and Technology Access Sanford School of Public Policy Duke University ICIUM November 2011

2. Hurdles to Drug Access Therapeutic Financial Structural Source: Health Action International-Peru R&D Pipeline Marketplace Delivery System

3. Where in the value chain to intervene? Pharmaceutical Manufacturer— Supplier Local BuyerProviderPharmacyConsumer Community management

4. Global Drug Facility Green Light Committee Gupta et al. “Responding to Market Failures in Tuberculosis Control.” Science (2011) 293 (5532): 1049-1051.

5. Affordable Medicines Facility for Malaria Pharmaceutical Manufacturer— Supplier Local BuyerProviderPharmacyConsumer AMFm Co-Payment Fund US$216 million Financed by UNITAID, Gates Foundation, DFID Supporting Interventions Up to US$ 126.7 million Financed by Global Fund

6. AMFm: Issues of Supply and Demand Source: AMFm, 2001. *These figures do not count co-payments through AMFm's Voluntary Pooled Procurement mechanism or ACTs purchased through the President's Malaria Initiative. Multinational corporations supply roughly one-third of co-pay approved treatments* SupplyDemand Source: Olusoji Adeyi, Affordable Medicines Facility- malaria (AMFm): Achievements to date, UNITAID Consultative Forum, October 4, 2011, Geneva. No. of treatments approved for co-payment

9. Source: Rutta, Edmund, et al. Increasing Access to Subsidized Artemisinin-based Combination Therapy through Accredited Drug Dispensing Outlets in Tanzania. Health Research Policy and Systems 2011; 9:22